CanSino Biologics, Inc. Class H (HK:6185) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
CanSino Biologics Inc. has received acceptance from China’s National Medical Products Administration for its new DTcP Infant vaccine, marking a significant step towards offering a domestic alternative to imported vaccines. This development not only strengthens CanSino’s product strategy but also enhances its competitiveness in the vaccine market.
For further insights into HK:6185 stock, check out TipRanks’ Stock Analysis page.
